세계의 틸드라키주맙(Tildrakizumab) 시장 보고서(2025년)

Tildrakizumab is a humanized monoclonal antibody that specifically targets the p19 subunit of interleukin-23 (IL-23), blocking its interaction with the IL-23 receptor. This action inhibits downstream inflammatory signaling, reducing the activation of pro-inflammatory cytokines and immune cells involved in autoimmune disorders such as plaque psoriasis.

The primary indications for tildrakizumab include plaque psoriasis, psoriatic arthritis, and other conditions. Plaque psoriasis is a chronic autoimmune skin disorder characterized by inflamed, scaly skin patches called plaques. The drug is available in both injectable and oral forms, distributed through hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end users, such as hospitals, specialty clinics, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The tildrakizumab market research report is one of a series of new reports from The Business Research Company that provides tildrakizumab market statistics, including the tildrakizumab industry global market size, regional shares, competitors with the tildrakizumab market share, detailed tildrakizumab market segments, market trends, and opportunities, and any further data you may need to thrive in the tildrakizumab industry. This tildrakizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tildrakizumab market size has grown rapidly in recent years. It will grow from $1.57 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the rise in the demand for the psoriasis treatment, rise in psoriasis prevalence, high prevalence of alcohol and smoking consumption, increase in research and development activities, increase in healthcare expenditure.

The tildrakizumab market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to growing prevalence of psoriasis, the rising initiative, rising prevalence of plaque psoriasis and psoriatic arthritis, growing awareness and education, high prevalence of alcohol and smoking consumption. Major trends in the forecast period include product innovations, combination therapies, shift toward biologic and targeted therapies, new injectable drugs, shift towards personalized medicine.

The forecast of 11.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of targeted psoriasis therapy by inflating prices of tildrakizumab autoinjectors manufactured in India and Switzerland, resulting in delayed treatment escalation and higher dermatology specialty costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of psoriasis is expected to drive the growth of the tildrakizumab market. Psoriasis is a chronic autoimmune disease that leads to rapid skin cell turnover, resulting in red, scaly patches on the skin. The increasing prevalence of psoriasis is linked to factors such as genetic predisposition, immune system dysfunction, environmental triggers, and lifestyle factors including stress, smoking, and obesity. Tildrakizumab helps treat psoriasis by specifically targeting interleukin-23 (IL-23), a cytokine responsible for promoting excessive skin cell growth and inflammation. This action helps reduce plaques, scaling, and redness. For example, in May 2024, the National Center for Biotechnology Information, a US-based national library of medicine, reported that in 2022, the prevalence of psoriatic arthritis (PsA) was 0.221%, with an incidence rate of 13.54 per 100,000 people. This is a significant increase compared to previous estimates, highlighting the growing prevalence of psoriasis and driving the tildrakizumab market.

The growth of the tildrakizumab market is also driven by improvements in healthcare facilities. These facilities, including hospitals, clinics, and diagnostic centers, provide essential medical care and services to treat and support patients. Healthcare facilities are advancing due to factors such as increased investments in healthcare infrastructure, a shift towards patient-centered care, population growth, and aging demographics. Enhanced healthcare facilities make it easier for patients to access advanced biologic treatments, improve diagnosis and referrals to specialists, ensure better management of biologic drugs, and increase healthcare provider awareness. All of these factors contribute to the adoption and effectiveness of tildrakizumab in treating chronic inflammatory conditions such as psoriasis. For instance, in May 2023, the American Health Care Association, a US-based nonprofit organization, reported that the number of hospitals in the United States increased to 6,129 in 2023, up by 0.591% from 6,093 hospitals in the previous year. This improvement in healthcare facilities is driving the growth of the tildrakizumab market.

Companies in the tildrakizumab market are also focused on developing innovative formulations, such as monoclonal antibody injections, to improve treatment efficacy and patient outcomes. Monoclonal antibody injections involve the use of laboratory-made antibodies that target specific antigens in the body for therapeutic or preventive purposes. For example, in May 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, received approval from the Chinese health authority, the National Medical Products Administration (NMPA), for tildrakizumab injections to treat plaque psoriasis. By targeting interleukin-23 (IL-23), a cytokine involved in inflammation that causes psoriasis, tildrakizumab helps reduce inflammation and slow the excessive growth of skin cells, improving symptoms such as redness, scaling, and plaque formation.

Major players in the tildrakizumab market are Sun Pharmaceutical Industries Ltd., Almirall S.A.

North America was the largest region in the tildrakizumab market in 2024. Asia-Pacific expected to be the fastest-growing region in the forecast period. The regions covered in tildrakizumab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tildrakizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tildrakizumab market consists of sales of single-dose vials and pre-filled syringes. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tildrakizumab Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tildrakizumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tildrakizumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tildrakizumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Other Indications
• 2) By Dosage Form: Injectable; Oral
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By End-User: Hospitals; Specialty Clinics; Homecare
• Subsegments:
• 1) By Plaque Psoriasis: Moderate Plaque Psoriasis; Severe Plaque Psoriasis; Treatment-Resistant Plaque Psoriasis
• 2) By Psoriatic Arthritis: Peripheral Psoriatic Arthritis; Axial Psoriatic Arthritis; Enthesitis-related Psoriatic Arthritis
• 3) By Other Indications: Inflammatory Skin Disorders; Off-Label Autoimmune Conditions; Emerging Therapeutic Applications
• Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Almirall S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tildrakizumab Market Characteristics

3. Tildrakizumab Market Trends And Strategies

4. Tildrakizumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Tildrakizumab Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tildrakizumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tildrakizumab Market Growth Rate Analysis
• 5.4. Global Tildrakizumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tildrakizumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tildrakizumab Total Addressable Market (TAM)

6. Tildrakizumab Market Segmentation

• 6.1. Global Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plaque Psoriasis
• Psoriatic Arthritis
• Other Indications
• 6.2. Global Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• 6.3. Global Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Tildrakizumab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• 6.5. Global Tildrakizumab Market, Sub-Segmentation Of Plaque Psoriasis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Moderate Plaque Psoriasis
• Severe Plaque Psoriasis
• Treatment-Resistant Plaque Psoriasis
• 6.6. Global Tildrakizumab Market, Sub-Segmentation Of Psoriatic Arthritis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral Psoriatic Arthritis
• Axial Psoriatic Arthritis
• Enthesitis-related Psoriatic Arthritis
• 6.7. Global Tildrakizumab Market, Sub-Segmentation Of Other Indications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inflammatory Skin Disorders
• Off-Label Autoimmune Conditions
• Emerging Therapeutic Applications

7. Tildrakizumab Market Regional And Country Analysis

• 7.1. Global Tildrakizumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tildrakizumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tildrakizumab Market

• 8.1. Asia-Pacific Tildrakizumab Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tildrakizumab Market

• 9.1. China Tildrakizumab Market Overview
• 9.2. China Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tildrakizumab Market

• 10.1. India Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tildrakizumab Market

• 11.1. Japan Tildrakizumab Market Overview
• 11.2. Japan Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tildrakizumab Market

• 12.1. Australia Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tildrakizumab Market

• 13.1. Indonesia Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tildrakizumab Market

• 14.1. South Korea Tildrakizumab Market Overview
• 14.2. South Korea Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tildrakizumab Market

• 15.1. Western Europe Tildrakizumab Market Overview
• 15.2. Western Europe Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tildrakizumab Market

• 16.1. UK Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tildrakizumab Market

• 17.1. Germany Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tildrakizumab Market

• 18.1. France Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tildrakizumab Market

• 19.1. Italy Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tildrakizumab Market

• 20.1. Spain Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tildrakizumab Market

• 21.1. Eastern Europe Tildrakizumab Market Overview
• 21.2. Eastern Europe Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tildrakizumab Market

• 22.1. Russia Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tildrakizumab Market

• 23.1. North America Tildrakizumab Market Overview
• 23.2. North America Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tildrakizumab Market

• 24.1. USA Tildrakizumab Market Overview
• 24.2. USA Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tildrakizumab Market

• 25.1. Canada Tildrakizumab Market Overview
• 25.2. Canada Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tildrakizumab Market

• 26.1. South America Tildrakizumab Market Overview
• 26.2. South America Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tildrakizumab Market

• 27.1. Brazil Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tildrakizumab Market

• 28.1. Middle East Tildrakizumab Market Overview
• 28.2. Middle East Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tildrakizumab Market

• 29.1. Africa Tildrakizumab Market Overview
• 29.2. Africa Tildrakizumab Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tildrakizumab Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tildrakizumab Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tildrakizumab Market Competitive Landscape And Company Profiles

• 30.1. Tildrakizumab Market Competitive Landscape
• 30.2. Tildrakizumab Market Company Profiles
  • 30.2.1. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Almirall S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Global Tildrakizumab Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Tildrakizumab Market

33. Recent Developments In The Tildrakizumab Market

34. Tildrakizumab Market High Potential Countries, Segments and Strategies

• 34.1 Tildrakizumab Market In 2029 - Countries Offering Most New Opportunities
• 34.2 Tildrakizumab Market In 2029 - Segments Offering Most New Opportunities
• 34.3 Tildrakizumab Market In 2029 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer